C07C307/10

Compositions for the treatment of pulmonary fibrosis
11401245 · 2022-08-02 · ·

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives

Provided is a compound of Formula (I): ##STR00001## wherein the variable groups are defined herein.

PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
20210220351 · 2021-07-22 ·

Described herein are methods for using compounds that activate pyruvate kinase.

PYRUVATE KINASE ACTIVATORS FOR USE IN THERAPY
20210220351 · 2021-07-22 ·

Described herein are methods for using compounds that activate pyruvate kinase.

COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
20210130301 · 2021-05-06 · ·

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS
20210130301 · 2021-05-06 · ·

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

Compositions for the treatment of pulmonary fibrosis
10919863 · 2021-02-16 · ·

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

Compositions for the treatment of pulmonary fibrosis
10919863 · 2021-02-16 · ·

The present invention relates to compounds and their use in the prophylactic and/or therapeutic treatment of pulmonary fibrosis and/or related conditions.

Prodrugs of phenolic TRPV1 agonists

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.

Prodrugs of phenolic TRPV1 agonists

Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.